By leveraging EEG biomarkers, Alto Neuroscience seeks to target patient subgroups in psychiatry by matching therapies to biology.
In the meeting, the firm will discuss with the agency new, positive three-month data from the pediatric cohort of the Phase I/II OPGx-LCA5-1001 trial.
Half of US commercial health plans add coverage limits for gene and cell therapies beyond what they're approved for, ...
The firms reported promising data from two trials of zipalertinib in patients who have received prior EGFR exon 20-directed therapy and those who haven't.
The development partners said they will share data with regulators, and AstraZeneca said it will harmonize its share listing across international stock exchanges.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback